trastuzumab

trastuzumab   Dan trastuzumab

Trastuzumab deruxtecan Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal

Trastuzumab deruxtecan is an effective new treatment for patients with HER2-positive metastatic breast cancer who have been previously treated trastuzumab A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2

ปิดvolte Key Message The ShortHER trial failed to demonstrate the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy The short Scottish Medicines Consortium decisions For trastuzumab · SMC No 92813 Trastuzumab for the treatment of adult patients